BioAge Labs, Inc.
BioAge Labs, Inc. (Nasdaq: BIOA) is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its platform uses longitudinal human datasets, molecular profiling and computational analysis to identify therapeutic targets associated with healthy… From the company’s description.
In fiscal 2025, BioAge Labs, Inc. reported revenue of $8.99M and a net loss of $80.61M. Operations used $81.63M in cash. Over the twelve months to Sep 30, 2026, revenue was $8.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioAge Labs, Inc. does
In the company’s own words
BioAge Labs, Inc. (Nasdaq: BIOA) is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its platform uses longitudinal human datasets, molecular profiling and computational analysis to identify therapeutic targets associated with healthy aging. Its lead candidate, BGE-102, is an oral, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiometabolic disease, including atherosclerotic cardiovascular disease risk reduction, and ophthalmology, initially diabetic macular edema. The company is also developing oral and injectable apelin receptor APJ agonists for obesity and advancing earlier-stage programs through collaborations with Eli Lilly and Novartis. BioAge’s platform comprises more than 150 million molecular data points from over 25,000 participant profiles, with health and functional follow-up spanning more than 50 years. The company’s pipeline is focused on chronic cardiometabolic diseases; the filing does not identify reportable business segments. Its website is https://bioagelabs.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1709941
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioAge Labs, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioAge Labs, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioAge Labs, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioAge Labs, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioAge Labs, Inc.'s last four quarterly filings that the numbers alone won't show?”